NRIX Live-Signale | Maximieren Sie Profite mit Getagraph.com

KAUFEN 104920 min ago

@ $9.02

Ausgestellt: 14 Feb 2024 @ 20:04

Rendite: 37.03%

Vorheriges Signal: Feb 14 - 15:30

Vorheriges Signal: Verkaufen

Rendite: 0.89 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 22:00):

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders...

Stats
Tagesvolumen	599 462
Durchschnittsvolumen	1.02M
Marktkapitalisierung	733.16M
EPS	$0 ( 2024-04-11 )
Nächstes Ertragsdatum	( $-0.720 ) 2024-07-11
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.65
ATR14	$0.0200 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-16	Van Houte Hans	Sell	6 812	Common Stock
2024-02-13	Van Houte Hans	Buy	150 000	Employee Stock Option (right to buy)
2024-02-13	Van Houte Hans	Buy	45 000	Restricted Stock Units
2024-02-13	Ring Christine	Buy	150 000	Employee Stock Option (right to buy)
2024-02-13	Ring Christine	Buy	45 000	Restricted Stock Units

INSIDER POWER
91.86
Last 100 transactions
Buy: 2 499 418 \| Sell: 108 263

Volumen Korrelation

Lang: -0.44 (neutral)

Kurz: 0.37 (neutral)

Signal:(51.965) Neutral

Nurix Therapeutics, Inc. Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Nurix Therapeutics, Inc. Korrelation - Währung/Rohstoff

-0.17
( neutral )

-0.20
( neutral )

0.00
( neutral )

-0.36
( neutral )

-0.10
( neutral )

-0.06
( neutral )

Nurix Therapeutics, Inc. Finanzdaten

Annual	2023
Umsatz:	$76.99M
Bruttogewinn:	$63.33M (82.26 %)
EPS:	$-2.65

FY	2023
Umsatz:	$76.99M
Bruttogewinn:	$63.33M (82.26 %)
EPS:	$-2.65

FY	2022
Umsatz:	$38.63M
Bruttogewinn:	$27.82M (72.02 %)
EPS:	$-3.42

FY	2021
Umsatz:	$29.75M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-2.64

Financial Reports:

No articles found.

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.